相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。METHYLGLYOXAL, A HIGHLY REACTIVE DICARBONYL COMPOUND, IN DIABETES, ITS VASCULAR COMPLICATIONS, AND OTHER AGE-RELATED DISEASES
C. G. Schalkwijk et al.
PHYSIOLOGICAL REVIEWS (2020)
Glyoxalase 1 Modulation in Obesity and Diabetes
Naila Rabbani et al.
ANTIOXIDANTS & REDOX SIGNALING (2019)
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Hiddo J. L. Heerspink et al.
LANCET (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies
Annabelle M. Warren et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Dicarbonyl Stress at the Crossroads of Healthy and Unhealthy Aging
Cecilia Nigro et al.
CELLS (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis
Raelene J. Pickering et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Urotensin II: Molecular Mechanisms of Biological Activity
Andrey A. Svistunov et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2018)
Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes
Nordin M. J. Hanssen et al.
DIABETES CARE (2018)
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Merlin C. Thomas et al.
DIABETOLOGIA (2018)
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R. Tuttle et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Quercetin, but Not Epicatechin, Decreases Plasma Concentrations of Methylglyoxal in Adults in a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial with Pure Flavonoids
Mathias D. G. Van den Eynde et al.
JOURNAL OF NUTRITION (2018)
The Effect of Sulforaphane on Glyoxalase I Expression and Activity in Peripheral Blood Mononuclear Cells
Michela Alfarano et al.
NUTRIENTS (2018)
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Marcel H. A. Muskiet et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
Ofri Mosenzon et al.
DIABETES CARE (2017)
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
Katherine R. Tuttle et al.
DIABETES OBESITY & METABOLISM (2017)
Urotensin II inhibits autophagy in renal tubular epithelial cells and induces extracellular matrix production in early diabetic mice
Guan-Jong Chen et al.
JOURNAL OF DIABETES INVESTIGATION (2017)
Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention
Sebastian Brings et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Polyphenols with antiglycation activity and mechanisms of action: A review of recent findings
Wan-Ju Yeh et al.
JOURNAL OF FOOD AND DRUG ANALYSIS (2017)
Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10-Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials
Costas Thomopoulos et al.
JOURNAL OF HYPERTENSION (2017)
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Marcel H. A. Muskiet et al.
NATURE REVIEWS NEPHROLOGY (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Resveratrol protects podocytes against apoptosis via stimulation of autophagy in a mouse model of diabetic nephropathy
Shan-Shan Huang et al.
SCIENTIFIC REPORTS (2017)
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial
Per-Henrik Groop et al.
DIABETES OBESITY & METABOLISM (2017)
NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy
Jay C. Jha et al.
DIABETES (2017)
Urinary adenosine excretion in type 1 diabetes
Harindra Rajasekeran et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2017)
Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes
Julie A. Lovshin et al.
DIABETES CARE (2017)
Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study
Nordin M. J. Hanssen et al.
DIABETES (2017)
The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Merlin C. Thomas
DIABETES & METABOLISM (2017)
Diabetes and Kidney Disease: Role of Oxidative Stress
Jay C. Jha et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
Metformin Scavenges Methylglyoxal To Form a Novel Imidazolinone Metabolite in Humans
Owen R. Kinsky et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2016)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation
Mingzhan Xue et al.
DIABETES (2016)
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
Jan H. Cornel et al.
DIABETES CARE (2016)
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Lennart Tonneijck et al.
DIABETES CARE (2016)
Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
J. Skov et al.
DIABETES OBESITY & METABOLISM (2016)
Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus
T. M. Jensen et al.
DIABETIC MEDICINE (2016)
Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
Lennart Tonneijck et al.
DIABETOLOGIA (2016)
Urotensin II Induces ER Stress and EMT and Increase Extracellular Matrix Production in Renal Tubular Epithelial Cell in Early Diabetic Mice
Xin-Xin Pang et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2016)
Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy
Satoru Takashima et al.
KIDNEY INTERNATIONAL (2016)
Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes
Muralikrishna Gangadharan Komala et al.
NEPHROLOGY (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Renoprotective Effects of Metformin are Independent of Organic Cation Transporters 1 & 2 and AMP-activated Protein Kinase in the Kidney
Michael Christensen et al.
SCIENTIFIC REPORTS (2016)
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses
Ferran Catala-Lopez et al.
PLOS MEDICINE (2016)
Therapeutic Targeting of the Mitochondria Initiates Excessive Superoxide Production and Mitochondrial Depolarization Causing Decreased mtDNA Integrity
Kaytee L. Pokrzywinski et al.
PLOS ONE (2016)
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
Mark E. Cooper et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Creatine Is a Scavenger for Methylglyoxal under Physiological Conditions via Formation of N-(4-Methyl-5-oxo-1-imidazolin-2-yl)sarcosine (MG-HCr)
Juergen Loebner et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2015)
Specific tandem mass spectrometric detection of AGE-modified arginine residues in peptides
Rico Schmidt et al.
JOURNAL OF MASS SPECTROMETRY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Association between Hemoglobin Concentration and the Progression or Development of Albuminuria in Diabetic Kidney Disease
Hiroshi Okada et al.
PLOS ONE (2015)
Skin Advanced Glycation End Products Glucosepane and Methylglyoxal Hydroimidazolone Are Independently Associated With Long-term Microvascular Complication Progression of Type 1 Diabetes
Saul Genuth et al.
DIABETES (2015)
New Insights Into Molecular Mechanisms of Diabetic Kidney Disease
Shawn S. Badal et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?
David Z. I. Cherney et al.
CANADIAN JOURNAL OF DIABETES (2014)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Sodium Glucose Transport 2 (SGLT2) Inhibition Decreases Glomerular Hyperfiltration Is There a Role for SGLT2 Inhibitors in Diabetic Kidney Disease?
Robert C. Stanton
CIRCULATION (2014)
Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system
Maria Paz Ocaranza et al.
CLINICAL SCIENCE (2014)
Knockdown of Glyoxalase 1 Mimics Diabetic Nephropathy in Nondiabetic Mice
Ferdinando Giacco et al.
DIABETES (2014)
Sodium- Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open- Label Proof- ofConcept Trial
Bruce A. Perkins et al.
DIABETES CARE (2014)
Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes
Olaf Brouwers et al.
DIABETOLOGIA (2014)
Angiotensin (1-7) prevents angiotensin II-induced nociceptive behaviour via inhibition of p38 MAPK phosphorylation mediated through spinal Mas receptors in mice
W. Nemoto et al.
EUROPEAN JOURNAL OF PAIN (2014)
Effect of Metformin on Methylglyoxal Metabolism in Patients with Type 2 Diabetes
Z. Kender et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2014)
Quercetin Inhibits Advanced Glycation End Product Formation by Trapping Methylglyoxal and Glyoxal
Xiaoming Li et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2014)
Nephropathy and Elevated BP in Mice with Podocyte-Specific NADPH Oxidase 5 Expression
Chet E. Holterman et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Genetic Targeting or Pharmacologic Inhibition of NADPH Oxidase Nox4 Provides Renoprotection in Long-Term Diabetic Nephropathy
Jay C. Jha et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
Dick de Zeeuw et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
Douglas Galasko et al.
NEUROLOGY (2014)
ACTIVATION OF THE ACE2/ANG-(1-7)/MAS PATHWAY REDUCES OXYGEN-GLUCOSE DEPRIVATION-INDUCED TISSUE SWELLING, ROS PRODUCTION, AND CELL DEATH IN MOUSE BRAIN WITH ANGIOTENSIN II OVERPRODUCTION
J. Zheng et al.
NEUROSCIENCE (2014)
Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
Naoto Terami et al.
PLOS ONE (2014)
Cardiovascular effects of the angiotensin type 2 receptor
Gabriel Faria-Costa et al.
REVISTA PORTUGUESA DE CARDIOLOGIA (2014)
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial
Katsuyuki Ando et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
Florian Gembardt et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
Yuji Ishibashi et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Urotensin-II promotes vascular smooth muscle cell proliferation through store-operated calcium entry and EGFR transactivation
Mara Rodriguez-Moyano et al.
CARDIOVASCULAR RESEARCH (2013)
NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus-Accelerated Atherosclerosis
Stephen P. Gray et al.
CIRCULATION (2013)
Urotensin II and the kidney
Robyn G. Langham et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2013)
Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
Per-Henrik Groop et al.
DIABETES CARE (2013)
Current therapeutic interventions in the glycation pathway: evidence from clinical studies
L. Engelen et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
Jeppe Skov et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Stimulation of ANP by angiotensin-(1-9) via the angiotensin type 2 receptor
Seung Ah Cha et al.
LIFE SCIENCES (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
MECHANISMS OF DIABETIC COMPLICATIONS
Josephine M. Forbes et al.
PHYSIOLOGICAL REVIEWS (2013)
Mechanisms of Nrf2/Keap1-Dependent Phase II Cytoprotective and Detoxifying Gene Expression and Potential Cellular Targets of Chemopreventive Isothiocyanates
Biswa Nath Das et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2013)
A novel natural Nrf2 activator with PPARγ-agonist (monascin) attenuates the toxicity of methylglyoxal and hyperglycemia
Wei-Hsuan Hsu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2013)
Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis
Hon-Yen Wu et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation
Mingzhan Xue et al.
BIOCHEMICAL JOURNAL (2012)
Urotensin II Stimulates Vascular Endothelial Growth Factor Secretion From Adventitial Fibroblasts in Synergy With Angiotensin II
Nana Song et al.
CIRCULATION JOURNAL (2012)
Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR
Mahboob Rahman et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Cellular and molecular mechanisms of metformin: an overview
Benoit Viollet et al.
CLINICAL SCIENCE (2012)
Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Jiwen (Jim) Liu et al.
DIABETES (2012)
Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis
P. Vejakama et al.
DIABETOLOGIA (2012)
Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose
Ki Mo Kim et al.
EXPERIMENTAL CELL RESEARCH (2012)
Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes
Karly C. Sourris et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Angiotensin-(1-9) Attenuates Cardiac Fibrosis in the Stroke-Prone Spontaneously Hypertensive Rat via the Angiotensin Type 2 Receptor
Monica Flores-Munoz et al.
HYPERTENSION (2012)
Resveratrol Upregulates Nrf2 Expression To Attenuate Methylglyoxal-Induced Insulin Resistance in Hep G2 Cells
An-Sheng Cheng et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2012)
Pyridoxamine, Advanced Glycation Inhibition, and Diabetic Nephropathy
Joline L. T. Chen et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Pyridorin in Type 2 Diabetic Nephropathy
Edmund J. Lewis et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy
Markus L. Alter et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Exenatide Reduces Urinary Transforming Growth Factor-beta(1) and Type IV Collagen Excretion in Patients with Type 2 Diabetes and Microalbuminuria
Hong Zhang et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
Peter Kolkhof et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Adenoviral Delivery of Angiotensin-(1-7) or Angiotensin-(1-9) Inhibits Cardiomyocyte Hypertrophy via the Mas or Angiotensin Type 2 Receptor
Monica Flores-Munoz et al.
PLOS ONE (2012)
Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats
Wei Jing Liu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Advanced Glycation Urinary Protein-Bound Biomarkers and Severity of Diabetic Nephropathy in Man
Melinda T. Coughlan et al.
AMERICAN JOURNAL OF NEPHROLOGY (2011)
Mutagenesis and Repair Induced by the DNA Advanced Glycation End Product N2-1-(Carboxyethyl)-2′-deoxyguanosine in Human Cells
Daniel Tamae et al.
BIOCHEMISTRY (2011)
Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy
Jianxin Lu et al.
CLINICAL BIOCHEMISTRY (2011)
The Role of Aldosterone in the Metabolic Syndrome
Marie Briet et al.
CURRENT HYPERTENSION REPORTS (2011)
Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes An Analysis From the CARDS Trial
Helen M. Colhoun et al.
DIABETES (2011)
Advanced Glycation End Products Are Direct Modulators of β-Cell Function
Melinda T. Coughlan et al.
DIABETES (2011)
Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration The Joslin 50-Year Medalist Study
Jennifer K. Sun et al.
DIABETES CARE (2011)
Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes
M. C. Thomas et al.
DIABETOLOGIA (2011)
Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by pericytes
F. Shimizu et al.
DIABETOLOGIA (2011)
HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation
Jose Augusto Nogueira-Machado et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Overexpression of Glyoxalase-I Reduces Hyperglycemia-induced Levels of Advanced Glycation End Products and Oxidative Stress in Diabetic Rats
Olaf Brouwers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension
Maria P. Ocaranza et al.
JOURNAL OF HYPERTENSION (2011)
Fisetin Lowers Methylglyoxal Dependent Protein Glycation and Limits the Complications of Diabetes
Pamela Maher et al.
PLOS ONE (2011)
Hyperglycemia Impairs Proteasome Function by Methylglyoxal
Markus A. Queisser et al.
DIABETES (2010)
Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes A 12-Year Follow-Up Study
Johanna W. M. Nin et al.
DIABETES (2010)
Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes
A. Koitka et al.
DIABETOLOGIA (2010)
Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor
K. C. Sourris et al.
DIABETOLOGIA (2010)
Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro
Maria Paz Ocaranza et al.
JOURNAL OF HYPERTENSION (2010)
Avosentan for Overt Diabetic Nephropathy
Johannes F. E. Mann et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
The RAAS in the pathogenesis and treatment of diabetic nephropathy
Piero Ruggenenti et al.
NATURE REVIEWS NEPHROLOGY (2010)
Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy
M. Sedeek et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2010)
Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy
Adeline L. Y. Tan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2010)
Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation
Shi Fang Yan et al.
ANNALS OF MEDICINE (2009)
Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients
Xiao Xiang Yan et al.
ATHEROSCLEROSIS (2009)
Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen
Kuo-Chu Chang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy - are these Receptors Valid Therapeutic Targets
Karly C. Sourris et al.
CURRENT DRUG TARGETS (2009)
High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study
N. Rabbani et al.
DIABETOLOGIA (2009)
Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study
J. W. M. Nin et al.
DIABETOLOGIA (2009)
Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene
Anastasia Z. Kalea et al.
FASEB JOURNAL (2009)
Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
Bastiaan E. de Galan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
RAGE-induced Cytosolic ROS Promote Mitochondrial Superoxide Generation in Diabetes
Melinda T. Coughlan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Subcellular localization of Nox4 and regulation in diabetes
Karen Block et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Plasma alpha-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients
Keisuke Nakayama et al.
AMERICAN JOURNAL OF NEPHROLOGY (2008)
Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-β1-mediated renal fibrosis and dysfunction
Lin Tian et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level
Biao Feng et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease
Regina Kunz et al.
ANNALS OF INTERNAL MEDICINE (2008)
Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis
Kikuo Isoda et al.
ATHEROSCLEROSIS (2008)
Over-expression of anglotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression
Changping Hu et al.
ATHEROSCLEROSIS (2008)
Over-expression of angiotensin II type 2 receptor (agtr2) decreases collagen accumulation in atherosclerotic plaque
Abhijit Dandapat et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes
Aino Soro-Paavonen et al.
DIABETES (2008)
Identification, classification, and expression of RAGE gene splice variants
Barry I. Hudson et al.
FASEB JOURNAL (2008)
In Skeletal Muscle Advanced Glycation End Products (AGEs) Inhibit Insulin Action and Induce the Formation of Multimolecular Complexes Including the Receptor for AGEs
Angela Cassese et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases
Ling Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes
Angelo A. Manfredi et al.
JOURNAL OF IMMUNOLOGY (2008)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial
Johannes F. E. Mann et al.
LANCET (2008)
Aliskiren combined with losartan in type 2 diabetes and nephropathy
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Telmisartan, ramipril, or both in patients at high risk for vascular events
Salim Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Urotensin-II and cardiovascular remodeling
Panayiota Papadopoulos et al.
PEPTIDES (2008)
Vasoactive hormones and the diabetic kidney
Christine Maric
THESCIENTIFICWORLDJOURNAL (2008)
Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-α-dependent pathway
Vicki Thallas-Bonke et al.
DIABETES (2008)
Supratherapeutic doses of angiotensin receptor Blockers to decrease proteinuria in patients with chronic kidney disease
Biff F. Palmer
AMERICAN JOURNAL OF NEPHROLOGY (2008)
Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo
Bernhard Moser et al.
JOURNAL OF IMMUNOLOGY (2007)
Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function
N. Rabbani et al.
KIDNEY INTERNATIONAL (2007)
Blockade of oxidative stress by vitamin C ameliorates albuminuria and renal sclerosis in experimental diabetic rats
Eun Young Lee et al.
YONSEI MEDICAL JOURNAL (2007)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
A. Patel et al.
LANCET (2007)
Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells
Y. Huang et al.
KIDNEY INTERNATIONAL (2007)
Activation of the renin-angiotensin system within podocytes in diabetes
T-H Yoo et al.
KIDNEY INTERNATIONAL (2007)
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE
Jane Tian et al.
NATURE IMMUNOLOGY (2007)
The emerging role of ACE2 in physiology and disease
I. Hamming et al.
JOURNAL OF PATHOLOGY (2007)
Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice
Cheol Whee Park et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes
Per M. Humpert et al.
CARDIOVASCULAR DIABETOLOGY (2007)
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension
Susan J. Zieman et al.
JOURNAL OF HYPERTENSION (2007)
Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension
Rogerio B. Wichi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2007)
Changes of gene expression profiles in macrophages stimulated by angiotensin II -: Angiotensin II induces MCP-2 through AT1-receptor
Atsuhito Tone et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2007)
Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism
Jennifer M. Sasser et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Angiotensin-(1-7): Pharmacology and new perspectives in cardiovascular treatments
Aaron J. Trask et al.
CARDIOVASCULAR DRUG REVIEWS (2007)
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy
Mark E. Williams et al.
AMERICAN JOURNAL OF NEPHROLOGY (2007)
The emerging role in angiotensin-converting enzyme-2 in the kidney
Kevin D. Burns
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2007)
Angiotensin II signal transduction through the AT(I) receptor: novel insig hts into mechanisms and pathophysiology
Sadaharu Higuchi et al.
CLINICAL SCIENCE (2007)
Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase
Carmine Savoia et al.
JOURNAL OF HYPERTENSION (2006)
Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes
Minghao Ye et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat
Maria Paz Ocaranza et al.
HYPERTENSION (2006)
Role of endothelin and endothelin receptor antagonists in renal disease
W. Neuhofer et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2006)
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
Murray Epstein et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
RAGE control of diabetic nephropathy in a mouse model -: Effects of RAGE gene disruption and administration of low-molecular weight heparin
Khin-Mar Myint et al.
DIABETES (2006)
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
K. J. Schjoedt et al.
KIDNEY INTERNATIONAL (2006)
Endothelin, the kidney, and hypertension
Joey P. Granger et al.
CURRENT HYPERTENSION REPORTS (2006)
ACE and ACE2 activity in diabetic mice
Jan Wysocki et al.
DIABETES (2006)
Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells
MA Reddy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats
Sang-Youb Han et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure
Thierno Pfab et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME
IF Benter et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Role of angiotensin type-1 and angiotensin type-2 receptors in the expression of vascular integrins in angiotensin II-infused rats
P Brassard et al.
HYPERTENSION (2006)
Chronic inhibition of nitric oxide production aggravates diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats
Hiroshi Kamijo et al.
NEPHRON PHYSIOLOGY (2006)
Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711)
Melpomeni Peppa et al.
AMERICAN JOURNAL OF NEPHROLOGY (2006)
The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure
DE Kohan
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2006)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: The impact of chronic kidney disease
PT Vlagopoulos et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress
PJ Beisswenger et al.
DIABETES (2005)
Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage
PA Voziyan et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy
JM Forbes et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy
CA Daly et al.
EUROPEAN HEART JOURNAL (2005)
NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy
M Satoh et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2005)
Effects of NADPH oxidase inhibitor in diabetic nephropathy
K Asaba et al.
KIDNEY INTERNATIONAL (2005)
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic - A report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
M Rahman et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure
WC Little et al.
JOURNAL OF CARDIAC FAILURE (2005)
Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes - The CALM II study
NH Andersen et al.
DIABETES CARE (2005)
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin:: randomised, double blind, placebo controlled trial (the DIABHYCAR study)
M Marre et al.
BRITISH MEDICAL JOURNAL (2004)
Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells
CY Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Role of nitric oxide in diabetic nephropathy
SS Prabhakar
SEMINARS IN NEPHROLOGY (2004)
AGEs activate mesangial TGF-β-Smad signaling via an angiotensin II type I receptor interaction
K Fukami et al.
KIDNEY INTERNATIONAL (2004)
Biochemical aspects of nitric oxide
S Mariotto et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
AH Barnett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Renal protective effect of YM598, a selective endothelia type A receptor antagonist
K Sugimoto et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2004)
Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice
A Flyvbjerg et al.
DIABETES (2004)
Advanced glycation end products activate Smad signaling via TGF-beta-dependent and -independent mechanisms: implications for diabetic renal and vascular disease
JH Li et al.
FASEB JOURNAL (2004)
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
JP Gutzwiller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review
GFM Strippoli et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Effect of angiotensin II on glomerular structure in streptozotocin-induced diabetic rats
SB Nicholas et al.
AMERICAN JOURNAL OF NEPHROLOGY (2004)
Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with type 2 diabetes mellitus: association with progress of diabetic nephropathy
K Totsune et al.
PEPTIDES (2004)
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy
WK Bolton et al.
AMERICAN JOURNAL OF NEPHROLOGY (2004)
Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism
GI Rice et al.
BIOCHEMICAL JOURNAL (2004)
Nephroprotective effect of Bosentan in diabetic rats
A Cosenzi et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2003)
Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain
T Sugo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Physiology and pathology of endothelin-1 in renal mesangium
A Sorokin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2003)
Liquid chromatography-based determination of urinary free and total N(epsilon)-(carboxymethyl)lysine excretion in normal and diabetic subjects
U Friess et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2003)
Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy
A Sato et al.
AMERICAN JOURNAL OF HYPERTENSION (2003)
Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas
RAS Santos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat
SS Ding et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2003)
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
M Yu et al.
JOURNAL OF HYPERTENSION (2003)
Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy
H Kusunoki et al.
DIABETES CARE (2003)
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
TM Wendt et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury
H Yonekura et al.
BIOCHEMICAL JOURNAL (2003)
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy
C Tikellis et al.
HYPERTENSION (2003)
Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells
S Yamagishi et al.
KIDNEY INTERNATIONAL (2003)
Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation
Y Inagaki et al.
DIABETOLOGIA (2003)
Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry
PJ Thornalley et al.
BIOCHEMICAL JOURNAL (2003)
Angiotensin AT1/AT2 receptors: Regulation, signalling and function
E Kaschina et al.
BLOOD PRESSURE (2003)
Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy:: effects of angiotensin converting enzyme inhibition
RG Langham et al.
DIABETOLOGIA (2002)
Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells
S Yamagishi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia
AO Hausse et al.
HEART (2002)
High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor
E Tsiani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2002)
β-cell death during progression to diabetes
D Mathis et al.
NATURE (2001)
Diabetes-associated sustained activation of the transcription factor nuclear factor-κB
A Bierhaus et al.
DIABETES (2001)
Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy
ME Cooper
DIABETOLOGIA (2001)
High glucose-enhanced mesangial cell extracellular signal-regulated protein kinase activation and α1 (IV) collagen expression in response to endothelin-1 -: Role of specific protein kinase C isozymes
H Hua et al.
DIABETES (2001)
Improved arterial compliance by a novel advanced glycation end-product crosslink breaker
DA Kass et al.
CIRCULATION (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
A Chrysostomou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
HH Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effects of endothelin receptor antagonists on the progression of diabetic nephropathy
B Hocher et al.
NEPHRON (2001)
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and Lisinopril microalbuminuria (CALM) study
CE Mogensen et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
A human homolog of angiotensin-converting enzyme - Cloning and functional expression as a captopril-insensitive carboxypeptidase
SR Tipnis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Diabetes mellitus increases endothelin-1 gene transcription in rat kidney
GM Hargrove et al.
KIDNEY INTERNATIONAL (2000)
A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
M Donoghue et al.
CIRCULATION RESEARCH (2000)
Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat
DJ Kelly et al.
KIDNEY INTERNATIONAL (2000)
分享论文
